Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab for treatment and prevention of gout flares in patients intolerant or unresponsive to NSAIDs/colchicine
2009-015018-23Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of canakinumab in gout and acute gout flare (2 arms), sponsored by Novartis. Primary endpoint: Time to complete resolution of pain in the most affected joint. Started Sep 2009; status: completed.
02
Drugs
canakinumab
03
Conditions
goutacute gout flare
Beyond the preview
Go deeper on 2009-015018-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015018-23.